SCHEMBL922690

SCHEMBL922690

NC1=NN=C(c2ccccc2)C1=NNc1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DEPTOR Q8TB45 1/20 0.50
ABCG2 Q9UNQ0 4/20 0.38
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TP53 P04637 2/20 0.37
TSHR P16473 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ABCC1 P33527 1/20 0.37
HTT P42858 1/20 0.36
ATR Q13535 1/20 0.35
MAPT P10636 3/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 2/20 0.35
ADORA2A P29274 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922689 1.00 DEPTOR (0.50) DEPTORABCG2MEN1KMT2ANPC1
SCHEMBL925048 0.92 DEPTOR (0.43) DEPTORABCG2MEN1KMT2ANPC1
SCHEMBL925049 0.92 DEPTOR (0.43) DEPTORABCG2MEN1KMT2ANPC1
SCHEMBL922439 0.90 DEPTOR (0.48) DEPTORKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL922438 0.90 DEPTOR (0.48) DEPTORKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL923896 0.89 DEPTOR (0.53) DEPTORMEN1KMT2ANPC1RAB9A
SCHEMBL922290 0.89 DEPTOR (0.47) DEPTORABCG2MEN1KMT2ANPC1
SCHEMBL922291 0.89 DEPTOR (0.47) DEPTORABCG2MEN1KMT2ANPC1
SCHEMBL923895 0.89 DEPTOR (0.53) DEPTORMEN1KMT2ANPC1RAB9A
SCHEMBL923166 0.88 DEPTOR (0.52) DEPTORMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US claimed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 DEPTOR 1170/4885ABCG2 1628/4885MEN1 3936/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 DEPTOR 1170/4885ABCG2 1628/4885MEN1 3936/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC DEPTOR 200/4885ABCG2 1942/4885MEN1 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.